Skip to Main Content

Paper Details

A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis.
Leukemia
271
2019
CKS1B, DNA drivers, Myeloma, NDMM, Patients, TP53, multiple myeloma, myeloma, patients
Author NameAffiliation
Konstantinos MavromatisCelgene Corporation
Fadi TowficCelgene Corporation
Daniel AuclairMultiple Myeloma Research Foundation
Jonathan J KeatsTranslational Genomics Research Institute
Alexander Keith StewartMayo Clinic
Sagar LonialWinship Cancer Institute, Emory University
Kenneth C AndersonDana-Farber Cancer Institute, Harvard Medical School
Kenneth C AndersonDana-Farber Cancer Institute, Harvard Medical School
  • 1 - 8

Datasets

Release 1.2